Skip to main content
. 2023 Jan 26;14:1096019. doi: 10.3389/fimmu.2023.1096019

Figure 5.

Figure 5

Impaired activation of IgD-negative naïve B cells after stimulation by IgM-BCR-, TLR7/9- or CD40 ligands (A) Representative dot blots showing expression of CD69 and CD86 on CD19+CD27-IgM+ IgD+ or IgD- naive B cells stimulated or not with F(ab)2 anti-IgM, Gardiquimod (TLR7), CpG (TLR9) or CD40L for 48 hours from a control individual (upper row) or an individual carrying a heterozygous IGHD variant. (B) Compiled data from 4 control individuals as well as 5 individuals carrying different IGHD variants (paired Student`s t-test; **, p < 0.01; *, p < 0.05).